Search Results Search Sort by RelevanceMost Recent Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865. Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029. State of the Art and Science Jul 2023 How Should We Approach Body Size Diversity in Clinical Trials? Dania Pagarkar, Erin Harrop, PhD, LICSW, and Lisa Erlanger, MD Despite concerns about clinical outcomes for patients with obesity, clinical trials report few data about such patients. AMA J Ethics. 2023;25(7):E517-527. doi: 10.1001/amajethics.2023.517. Viewpoint Sep 2016 The Limits of Informed Consent for an Overwhelmed Patient: Clinicians’ Role in Protecting Patients and Preventing Overwhelm Johan Bester, MBChB, MPhil, Cristie M. Cole, JD, and Eric Kodish, MD Protecting patients rather than informed consent should be the goal when the complexity of information overwhelms patients’ decision-making capacity. AMA J Ethics. 2016;18(9):869-886. doi: 10.1001/journalofethics.2016.18.9.peer2-1609. Podcast Jul 2023 Author Interview: “How Should We Approach Body Size Diversity in Clinical Trials?” Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”
Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865.
Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029.
State of the Art and Science Jul 2023 How Should We Approach Body Size Diversity in Clinical Trials? Dania Pagarkar, Erin Harrop, PhD, LICSW, and Lisa Erlanger, MD Despite concerns about clinical outcomes for patients with obesity, clinical trials report few data about such patients. AMA J Ethics. 2023;25(7):E517-527. doi: 10.1001/amajethics.2023.517.
Viewpoint Sep 2016 The Limits of Informed Consent for an Overwhelmed Patient: Clinicians’ Role in Protecting Patients and Preventing Overwhelm Johan Bester, MBChB, MPhil, Cristie M. Cole, JD, and Eric Kodish, MD Protecting patients rather than informed consent should be the goal when the complexity of information overwhelms patients’ decision-making capacity. AMA J Ethics. 2016;18(9):869-886. doi: 10.1001/journalofethics.2016.18.9.peer2-1609.
Podcast Jul 2023 Author Interview: “How Should We Approach Body Size Diversity in Clinical Trials?” Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”